

**Pharmapar Inc**  
**Balance Sheet as at March 31, 2025**

	Note No.	Amount in CAD	
		31-Mar-25	31-Mar-24
<b>A ASSETS</b>			
<b>TOTAL ASSETS</b>		-	-
<b>B EQUITY AND LIABILITIES</b>			
<b>I Equity</b>			
(a) Equity share capital	1	5,000,397	5,000,397
(b) Reserves and Surplus	2	(8,277,156)	(8,277,156)
<b>Total Equity</b>		<b>(3,276,759)</b>	<b>(3,276,759)</b>
<b>II Liabilities</b>			
<b>1 Non-current liabilities</b>			
(a) Financial liabilities			
(i) Borrowings	3	2,525,621	2,525,621
<b>Total non-current liabilities</b>		<b>2,525,621</b>	<b>2,525,621</b>
<b>2 Current liabilities</b>			
(a) Financial liabilities			
(i) Trade payables	4	129,688	129,687
(ii) Other financial liabilities	5	434,923	434,923
(b) Provisions	6	186,528	186,528
<b>Total current liabilities</b>		<b>751,138</b>	<b>751,138</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>0</b>	<b>(0)</b>

**Pharmapar Inc**  
**Statement of Profit And Loss for the Year Ended March 31, 2025**

	Particulars	Note No.	Amount in CAD	
			31-Mar-25	31-Mar-24
<b>1</b>	<b>Total Revenue</b>		-	-
<b>2</b>	<b>Expenses</b>			
	(a) Cost of material consumed		-	-
	(b) Employee benefits expense	7	-	15,000
	(c) Finance costs	8	-	45,983
	(d) Other expenses	9	-	62,232
	<b>Total expenses</b>		-	<b>123,215</b>
<b>3</b>	<b>Profit / (Loss) before exceptional items and taxes (1-2)</b>		-	<b>(123,215)</b>
<b>4</b>	<b>Exceptional Item</b>	10	-	(642,106)
<b>5</b>	<b>Profit / (Loss) before taxes (3+4)</b>		-	<b>(765,321)</b>
<b>6</b>	<b>Tax Expense:</b>			
	(a) Current tax		-	-
	Total tax expenses		-	-
<b>7</b>	<b>Profit / (Loss) for the year after tax</b>		-	<b>(765,321)</b>

Pharmapar Inc  
Notes forming part of financial statement

Note No.

<b>1</b>	<b>Share capital</b>	<b>Amount in CAD</b>	
	<b>Particulars</b>	<b>31-Mar-25</b>	<b>31-Mar-24</b>
	Issued, subscribed and fully paid-up Equity share capital	5,000,397	5,000,397
	<b>Total</b>	<b>5,000,397</b>	<b>5,000,397</b>

  

<b>2</b>	<b>Reserves and surplus</b>	<b>Amount in CAD</b>	
	<b>Particulars</b>	<b>31-Mar-25</b>	<b>31-Mar-24</b>
	<b>Surplus in statement of profit and loss</b>		
	Opening balance	(8,277,156)	(7,511,835)
	Add: Profit / (Loss) for the year	-	(765,321)
	<b>Closing balance</b>	<b>(8,277,156)</b>	<b>(8,277,156)</b>
	<b>Total</b>	<b>(8,277,156)</b>	<b>(8,277,156)</b>

  

<b>3</b>	<b>Long term borrowings</b>	<b>Amount in CAD</b>	
	<b>Particulars</b>	<b>31-Mar-25</b>	<b>31-Mar-24</b>
	Loan from related Parties	2,525,621	2,525,621
	<b>Total</b>	<b>2,525,621</b>	<b>2,525,621</b>

  

<b>4</b>	<b>Trade payables</b>	<b>Amount in CAD</b>	
	<b>Particulars</b>	<b>31-Mar-25</b>	<b>31-Mar-24</b>
	Trade payable	129,688	129,687
	<b>Total</b>	<b>129,688</b>	<b>129,687</b>

  

<b>5</b>	<b>Other Current financial Liabilities</b>	<b>Amount in CAD</b>	
	<b>Particulars</b>	<b>31-Mar-25</b>	<b>31-Mar-24</b>
	Payable to group entities	434,923	434,923
	<b>Total</b>	<b>434,923</b>	<b>434,923</b>

  

<b>6</b>	<b>Provisions</b>	<b>Amount in CAD</b>	
	<b>Particulars</b>	<b>31-Mar-25</b>	<b>31-Mar-24</b>
	Provision for Taxation	186,529	186,528
	<b>Total</b>	<b>186,529</b>	<b>186,528</b>

  

<b>7</b>	<b>Employee benefit expenses</b>	<b>Amount in CAD</b>	
	<b>Particulars</b>	<b>31-Mar-25</b>	<b>31-Mar-24</b>
	Salaries and wages	-	15,000
	<b>Total</b>	<b>-</b>	<b>15,000</b>

**Pharmapar Inc**

**Notes forming part of financial statement**

**Note No.**

**8 Finance cost**

**Amount in CAD**

<b>Particulars</b>	<b>31-Mar-25</b>	<b>31-Mar-24</b>
Bank charges	-	200
Interest cost	-	45,783
<b>Total</b>	<b>-</b>	<b>45,983</b>

**9 Other expenses**

**Amount in CAD**

<b>Particulars</b>	<b>31-Mar-25</b>	<b>31-Mar-24</b>
Rates & taxes	-	56,232
Communication expenses	-	1,000
Professional fees & Legal fees	-	5,000
<b>Total</b>	<b>-</b>	<b>62,232</b>

**10 Exceptional items**

**Amount in CAD**

<b>Particulars</b>	<b>31-Mar-24</b>	<b>31-Mar-24</b>
Impairment and write down of assets	-	(642,106)
<b>Total</b>	<b>-</b>	<b>(642,106)</b>